Clopidogrel is an inhibitor of the P2Y12 platelet receptor but testing to demonstrate a drug effect is controversial since there are often discordant results between different tests methods.
Methods
Samples from patients taking clopidogrel prior to intracranial flow-diversion procedures were tested using light transmission aggregometry (LTA), whole blood impedance aggregometry (WBIA) and the VerifyNow device (VND). Samples were classified as concordant if all test results were either responsive (inhibition) or resistant. Discordant results were separated using the VND into those with a responsive versus a resistant test result.
Results
Samples from 96 patients were studied. Concordance for all three tests was seen in 53/96 (55%) of samples, of which 41 (43%) were responsive and 12 (12%) were resistant. Discordance was observed in 43 samples (45%), 37 (28%) of which were caused by responsive VND and either a resistant WBIA or LTA and 6 (7%) of which were caused by a resistant VND but a responsive test result using either WBIA or LTA. These two discordant groups differed in both platelet count and hematocrit, but no such difference was present between the two concordant groups.
Conclusion
Discordance in P2Y12 inhibition testing may be partly explained by sample platelet count and hematocrit.
ColletJPMontalescotG. Platelet function testing and implications for clinical practice. J Cardiovasc Pharm Ther2009; 14: 157–169.
4.
GroveELStoreyRFWurtzM. Platelet function testing in atherothrombotic disease. Curr Pharm Design2012; 18: 5379–5391.
5.
Dyszkiewicz-KorpantyAOltenanuHFrenkelEP, et al.Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, and the platelet function analyzer (PFA-100TM). Platelets2007; 18: 491–496.
6.
BreetNvan WerkumJWBoumanHJ, et al.Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA2010; 303: 754–762.
7.
FletchtenmacherNDittmerKRMichaelsBP, et al.Clopidogrel resistance in neurovascular stenting: correlations between light transmission aggregometry, VerifyNow and the multiplate. Am J Neuroradiol2015; 36: 1953–1958.
8.
BornGV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature1962; 194: 927–929.
9.
BreddinHK. Can platelet aggregometry be standardized?Platelets2005; 16: 151–158.
10.
LinnemannBSchwonbergJManiH, et al.Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost2008; 4: 677–683.
11.
FrelingerALGachetCMumfordAD, et al.Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. J Thromb Haemostasis2018; 16: 2341–2346.
12.
CardinalDCFlowerRJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods1980; 3: 135–158.
13.
MackieIJJonesRMachinSJ. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J Clin Pathol1984; 37: 874–878.
14.
TanLAKeigherKMMunichSA, et al.Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J Neurointervent Surg2015; 7: 217–221.
15.
McTaggartRAChoudhriOAMarcellusML, et al.Use of thromboelastography to tailor dual antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the pipeline embolization device. J NeuroIntervent Surg2015; 7: 425–430.
16.
TaylorLIDickersonJCDambrinoRJ, et al.Platelet testing in flow diversion: a review of the evidence. Neurosurg Focus2017; 42: 1–8.
17.
IvandicBTSchlickPStaritzP, et al.Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem2006; 52: 383–388.
18.
HuHForslundMNailinL. Influence of extracellular calcium on single platelet activation as measured by whole blood flow cytometry. Thromb Res2005; 116: 241–247.
SweeneyJDLabuzettaJWMichielsonCE, et al.Whole blood aggregation using impedance and particle counter methods. Am J Clin Pathol1989; 92: 794–797.
21.
SeyfertUTHaubeltHVogtA, et al.Variables influencing multiplate whole blood impedance aggregometry and turbimetric platelet aggregation in healthy individuals. Platelets2007; 18: 199–206.
22.
PriceMJEndemannSGollapudiRR, et al.Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug eluting stent implantation. Eur Heart J2008; 29: 992–1000.
23.
MarcucciRGoriAMPanicciaR, et al.Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care device. Circulation2009; 119: 237–242.
24.
AradiDKirtaneABonelloL, et al.Bleeding and stent thrombosis on P2Y12 inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J2015; 36: 1762–1771.
25.
SweeneyJDLabuzettaJWFitzpatrickJE. The effect of the platelet count on the aggregation response and adenosine triphosphate release in an impedance lumi-aggregometer. Am J Clin Pathol1988; 89: 655–659.
26.
SweeneyJDLabuzettaJWBernsteinZP, et al.Ristocetin induced platelet aggregate formation and adherence to the probe of an impedance aggregometer. Am J Clin Path1990; 93: 548–551.
27.
SweeneyJDHoernigLAFitzpatrickJE. Whole blood aggregation in von Willebrand disease. Am J Hematol1989; 32: 190–193.
28.
JarvisGEHumphriesRGRobertsonMJ, et al.ADP Can induce aggregation of human platelets via both P2Y1 and P2T receptors. Br J Pharmacol2000; 129: 275–282.
29.
AngiolilloDJFernandez-OrtizABernardoE, et al.Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol2007; 49: 1505–1516.
30.
LeeDHAratAMorsiH, et al.Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. Am J Neuroradiol2008; 29: 1389–1394.
